Novalis Biotechnology Incubation

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Alithea Genomics is a Switzerland-based company specializing in RNA sequencing and transcriptomics. Leveraging its expertise in bioengineering, molecular biology, and genomics, the company has developed proprietary technology aimed at enhancing the efficiency of Ribonucleic acid sequencing. This technology not only reduces operational costs but also significantly increases the throughput of analyzed samples. As a result, Alithea Genomics provides pharmaceutical companies with the tools necessary for advanced biomedical research and discoveries, enabling them to accelerate their development processes and improve research outcomes.

Altavo is a medical device startup focused on developing innovative solutions for individuals who have lost their ability to speak due to surgery or disease. The company leverages advanced machine learning and cutting-edge sensor technology to create custom, natural-sounding artificial voices. By employing speech recognition and synthesis techniques, Altavo aims to restore the ability to communicate, significantly enhancing the quality of life for those with speech disorders. Through its innovative approach, Altavo addresses a critical need in the healthcare sector, providing voiceless individuals with a means to express themselves effectively.

Rarity Bioscience is a biotechnology company that specializes in developing advanced molecular amplification technology for the detection of nucleic acid sequences. The company’s primary focus is on creating ultrasensitive multiplex assays capable of identifying small amounts of DNA sequence variants in biological samples, particularly in liquid biopsies. This innovative platform provides valuable tools for both research and clinical applications, enhancing the ability of physicians to detect rare genetic variations that may be critical for diagnosis and treatment. Through its technology, Rarity Bioscience aims to improve the precision and effectiveness of molecular diagnostics.

C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care through point-of-care solutions. The company specializes in ambulant diagnostic devices that facilitate blood coagulation testing, allowing patients to perform up to twelve different reactions using a small volume of blood. This technology is designed to empower patients to conduct tests in various settings, including at home, while traveling, or in critical care environments, all without the need for traditional laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve quality of life while maintaining cost-effectiveness in healthcare.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

Alithea Genomics is a Switzerland-based company specializing in RNA sequencing and transcriptomics. Leveraging its expertise in bioengineering, molecular biology, and genomics, the company has developed proprietary technology aimed at enhancing the efficiency of Ribonucleic acid sequencing. This technology not only reduces operational costs but also significantly increases the throughput of analyzed samples. As a result, Alithea Genomics provides pharmaceutical companies with the tools necessary for advanced biomedical research and discoveries, enabling them to accelerate their development processes and improve research outcomes.

Trince is a biotechnology company focused on advancing cell-based science and therapeutics through innovative cell transfection technology. The company specializes in the delivery of molecules into cells both in vitro and ex vivo, utilizing a platform that integrates laser exposure with photothermal nanoparticles. This technology converts light energy into heat, allowing for the transient permeabilization of the cellular plasma membrane. As a result, Trince enables clients to introduce genetic material into cells efficiently and at high throughput, thereby enhancing research and therapeutic applications in the life sciences sector.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

RheaVita is a pharmaceutical company specializing in the development of innovative continuous freeze-drying technology for biopharmaceutical products. This technology integrates all essential freeze-drying process steps into a continuous production line, allowing for the constant infeed of products and simultaneous outfeed of dried products. By employing this advanced manufacturing approach, RheaVita addresses scale-up challenges and significantly reduces cycle times, facilitating faster product development and quicker time-to-market. The process also lowers production costs and minimizes the need for extensive manufacturing facilities and clean room space. Additionally, RheaVita's technology enhances quality assurance through comprehensive inspection methods and offers the potential for real-time product release, resulting in improved and uniform product quality as well as process consistency.

Grapheal is a Medtech startup focused on developing innovative embedded and wearable biosensors designed for modern healthcare applications. Leveraging advanced graphene transistors, Grapheal's devices enable accurate and affordable field diagnostics and remote patient monitoring. Their biosensors, which are minimalistic in design and integrated with wireless connectivity, allow for the precise detection of biomarkers and pathogens, all accessible through a smartphone. The company’s approach encompasses the entire value chain, from synthesizing proprietary sensing nanomaterials to the integration of sensor technology with embedded data analysis and software development, thus facilitating enhanced medical oversight for professionals.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care through point-of-care solutions. The company specializes in ambulant diagnostic devices that facilitate blood coagulation testing, allowing patients to perform up to twelve different reactions using a small volume of blood. This technology is designed to empower patients to conduct tests in various settings, including at home, while traveling, or in critical care environments, all without the need for traditional laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve quality of life while maintaining cost-effectiveness in healthcare.